UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells

PloS one, 2013-04, Vol.8 (4), p.e62334

2013

Link zum Volltext

Verfügbarkeit prüfen

Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells

PloS one, 2012-05, Vol.7 (5), p.e38278

2012

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Clinical cancer research, 2024-01, Vol.30 (1), p.39

2024

Link zum Volltext

Verfügbarkeit prüfen

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Clinical cancer research, 2022-10, Vol.28 (20), p.4587-4587

2022

Link zum Volltext

Verfügbarkeit prüfen

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

Oncotarget, 2020-04, Vol.11 (17), p.1478-1492

2020

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the genomic determinants of response to CDK4/6 inhibitors

Oncotarget, 2018-12, Vol.9 (96), p.36822-36823

2018

Link zum Volltext

Verfügbarkeit prüfen

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer

Oncotarget, 2015-09, Vol.6 (27), p.23548-23560

2015

Link zum Volltext

Verfügbarkeit prüfen

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

International journal of oncology, 2014-04, Vol.44 (4), p.1365-1375

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 766: Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.766-766

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.785-785

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD2-06: Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD2-06-PD2-06

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2214: COUP-TFII suppresses NFκB activation in endocrine-resistant breast cancer cells

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2214-2214

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4458: Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4458-4458

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor

Clinical cancer research, 2023-06

2023

Link zum Volltext

Verfügbarkeit prüfen

[beta]-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

International journal of oncology, 2014-04, Vol.44 (4), p.1365

2014

Link zum Volltext

Verfügbarkeit prüfen

Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor [beta] Transcription in Breast Cancer Cells

PloS one, 2012-05, Vol.7 (5), p.e38278

2012

Link zum Volltext

Verfügbarkeit prüfen

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis

PloS one, 2014-08, Vol.9 (8), p.e104521-e104521

2014

Link zum Volltext

Verfügbarkeit prüfen

postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1117-TPS1117

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD2-09-PD2-09

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells

Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

Unraveling the genomic determinants of response to CDK4/6 inhibitors

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

Abstract 766: Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant

Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Abstract PD2-06: Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

Abstract 2214: COUP-TFII suppresses NFκB activation in endocrine-resistant breast cancer cells

Abstract 4458: Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant

Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer

Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor

[beta]-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor [beta] Transcription in Breast Cancer Cells

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis

postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)

Aktive Filter

Suchergebnisse filtern